Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

443

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

June 10, 2025

Study Completion Date

May 31, 2027

Conditions

Cervical Cancer

Interventions

DRUG

camrelizumab； famitinib malate

Camrelizumab intravenously ; Famitinib Orally

DRUG

platinum-based chemotherapy

Physician's choice chemotherapy

Trial Locations (1)

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY